Gene-expression profiling in differentiated thyroid cancer--a viable strategy for the practice of genomic medicine?
Thyroid neoplasias have been largely ignored as an active field of investigation due to the overall favorable prognosis of differentiated nonmedullary thyroid cancers. However, differentiated thyroid cancers have the highest estimated annual percentage increase in incidence amongst all cancer sites. Furthermore, no significant progress has been made to improve survival, especially for advanced disease. Compounding the problem, there remains a lack of highly accurate preoperative markers or molecular-based predictive models to differentiate benign from malignant follicular neoplasias, thus we continue to rely upon surgery for diagnostic purposes in this subset of patients. Therefore, new approaches are necessary to identify potential novel diagnostic, prognostic and therapeutic algorithms, which would not only allow accurate early diagnosis but also personalized patient management, with clinical management and surveillance tailored according to the genetic signature of the patient. The advent of modern genomic technologies, such as global gene-expression profiling, may begin to provide the data required for the evidence-based practice of genomic medicine as it relates to thyroid neoplasia. However, it is already clear that genomic technology alone is insufficient to fully achieve this vision.
The Ohio State University, Human Cancer Genetics Program, 420 West 12th Avenue, Ste 690 TMRF, Columbus, OH 43210, USA.
Frank
F
Weber
Charis
C
Eng
D018263:Adenocarcinoma, Follicular / Q000175:diagnosis / Q000235:genetics*; D020869:Gene Expression Profiling; D023281:Genomics; D006801:Humans; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000235:genetics*